Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118112 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL15521126 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29362168 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL31248559 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8227161 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL20592813 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL20592811 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29759385 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29493132 | 0.92 | MDM2 (0.53) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL8226910 | 0.92 | MDM4 (0.50) | MDM4TP53CASP3KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011107-A | Polypeptide, preparation method thereof and application thereof in delaying muscle attenuation | 内蒙古蒙牛乳业（集团）股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | SHANGHAI UNIVERSITY (CN) | 2025-10-23 | — | — | US | claimed |
| CN-120058862-A | Precursor compound of targeting human PD-L1, radiolabel and preparation method and application thereof | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 2025-05-30 | — | — | CN | claimed |
| CN-119350469-B | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119798397-A | Mu-conopeptide analogue and preparation method thereof | 深圳百川泓沛生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119735645-A | Method for preparing terlipressin through solid phase | 辰欣药业股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-113717246-B | Preparation method of polypeptide heterodimer | 核欣(苏州)医药科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119661685-A | Canagliflozin peptide synthesis method | 杭州思诺达医药科技有限责任公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119161446-B | Process for preparing amylin analogues | 杭州诺泰诺和生物医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119371515-A | Synthesis method of salmon calcitonin acetylation impurity | 翰宇药业（武汉）有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-112094324-B | Synthesis method of carbetocin | 宁波三生生物科技股份有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-112062813-B | Synthesis method of desmopressin | 翰宇药业（武汉）有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-112175067-B | Preparation method of teduglutide | 深圳市星银医药有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114044813-B | Preparation and purification method of procatide | 浙江湃肽生物有限公司南京分公司 | 2022-04-15 | — | — | CN | claimed |
| CN-113135988-B | Preparation method of thymosin beta 4 | 润辉生物技术（威海）有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-112142825-B | Method for synthesizing carbetocin in fragment mode | 山东辰龙药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-114057862-A | Synthetic method of GLP-1(1-37) polypeptide | 安徽省国平药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114044813-A | Preparation and purification method of procatide | 浙江湃肽生物有限公司南京分公司 | 2022-02-15 | — | — | CN | claimed |
| CN-109180803-B | Somatostatin and preparation method and pharmaceutical composition thereof | 成都天台山制药有限公司 | 2022-02-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | STING1, CGAS, VIP | MDM4 1661/4885TP53 1709/4885CASP3 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.